The ALS Association is celebrating the third anniversary of the ALS Ice Bucket Challenge with a new awareness and fund-raising campaign to support the amyotrophic lateral sclerosis (ALS) community. The new campaign, “Every Drop Adds Up,” with the help of Kwittken, a global communications agency, aims…
Increasing the production of the muscle protein Dok-7 may be a way to treat the muscle weakness in ALS, a Japanese study reports. The research, “DOK7 genes therapy enhances motor activity and life span in ALS model mice,” was published in the journal EMBO Molecular Medicine. A hallmark…
William White, who entered Ohio State University on a football scholarship, played for the Buckeyes and earned an engineering degree before going on to an 11-year NFL career with the Detroit Lions, the Kansas City Chiefs, and the Atlanta Falcons. William White Now retired from the NFL and…
Researchers have found a way to break down aggregated RNA molecules that cause diseases such as certain inherited forms of amyotrophic lateral sclerosis (ALS). As the technique has the potential to treat several diseases which currently lack treatment options, the research team from the University of California, San Diego (UCSD)…
Radicava (edaravone), the first new medication for amyotrophic lateral sclerosis (ALS) in 22 years, is now available in the United States. Approved May 5 by the U.S. Food and Drug Administration (FDA) for all U.S. adults diagnosed with ALS, Radicava has been shown to slow the loss of physical function in ALS patients by…
Brazilian doctors have begun prescribing HempMeds Brasil‘s hemp cannabis oil to ALS and psoriasis patients, the company’s U.S. parent reports. San Diego-based Medical Marijuana said it is the first time Brazilian physicians have prescribed the product, known as Real Scientific Hemp Oil, to those with the two diseases. HempMeds Brasil…
BrainStorm Cell Therapeutics has appointed a new vice president of patient advocacy and government affairs, a move intended to reinforce the company’s commitment to the amyotrophic lateral sclerosis (ALS) community. The new vice president, Mary Kay Turner, brings more than two decades of experience in biotech and pharmaceutical advocacy…
Amylyx Pharmaceuticals has dosed the first patient in a Phase 2 clinical trial that will assess AMX0035’s ability to treat amyotrophic lateral sclerosis. Researchers are seeking 132 participants for the CENTAUR study (NCT03127514). A unique feature of the trial is that Amylyx designed it in collaboration with patients and caregivers…
Alabama-based Southern Research has appointed neurodegenerative diseases expert Rita Cowell as chair of its neuroscience department to help expand research into potential cures for amyotrophic lateral sclerosis (ALS) and other diseases like Alzheimer’s and Parkinson’s. Cowell’s work has focused on the root causes of why people develop neurodegenerative diseases that lack…
Amyotrophic lateral sclerosis may have more in common with other neurodegenerative and psychiatric diseases than previously assumed, a study indicates. It concluded that those with ALS are also more likely to develop another neurodegenerative or psychiatric disorder. And the reverse is also true: Those with a neurodegenerative disease or a psychiatric condition…
